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Background: Uro-oncological neoplasms have both a high incidence and mortality rate and are therefore a major
public health problem. The aim of this study was to evaluate research activity in uro-oncology over the last decade.
Methods: We searched MEDLINE and ClinicalTrials.gov systematically for studies on prostatic, urinary bladder, kidney,
and testicular neoplasms. The increase in newly published reports per year was analyzed using linear regression. The
results are presented with 95% confidence intervals, and a p value <0.05 was considered statistically significant.
Results: The number of new publications per year increased significantly for prostatic, kidney and urinary bladder
neoplasms (all <0.0001). We identified 1,885 randomized controlled trials (RCTs); also for RCTs, the number of newly
published reports increased significantly for prostatic (p = 0.001) and kidney cancer (p = 0.005), but not for bladder
(p = 0.09) or testicular (p = 0.44) neoplasms. We identified 3,114 registered uro-oncological studies in ClinicalTrials.gov.
However, 85% of these studies are focusing on prostatic (45%) and kidney neoplasms (40%), whereas only 11% were
registered for bladder cancers.
Conclusions: While the number of publications on uro-oncologic research rises yearly for prostatic and kidney
neoplasms, urothelial carcinomas of the bladder seem to be neglected despite their important clinical role. Clinical
research on neoplasms of the urothelial bladder must be explicitly addressed and supported.
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neoplasmsBackground
Uro-oncological neoplasms have both a high incidence and
mortality rate [1,2]. Urological neoplasms are therefore a
major public health problem [3]. The treatment of prostatic
neoplasms costs 11.85 billion dollars, representing 15% of
the average annual cost for the treatment of all cancers in
the United States (http://www.cancer.gov). In 2010, the
treatment cost for urinary bladder and renal cancers
in the United States was 3.98 billion and 3.80 billion* Correspondence: frank.kunath@uk-erlangen.de
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reproduction in any medium, provided the oruro-oncological research should pursue two major
goals. On the one hand, patient-centered care must
be optimized; on the other hand, it must be regulated
effectively. Generating high quality studies is indispensable
to provide treatments based on the best clinical evidence
available. However, it is not clear whether current scientific
research output adequately addresses clinical requirements
of this population. The aim of this study was to investigate
current research activity in the field of uro-oncology.Methods
This analysis focused on scientific publications in the
field of uro-oncology. Where appropriate, the systematic
literature search was designed, conducted, and reportedLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Expanded search strategy for the MeSH term
‘urinary bladder neoplasms’ in MEDLINE
Neoplasm, urinary bladder Bladder neoplasm
Urinary bladder neoplasm Neoplasm bladder
Bladder tumors Urinary bladder cancer
Bladder tumor Cancer, urinary bladder
Tumor, bladder Cancer of bladder
Tumors, bladder Cancer of the bladder
Neoplasms, bladder Bladder cancer
Bladder neoplasms Bladder cancers
Cancer, bladder
Table 3 Expanded search strategy for urinary bladder
neoplasms in ClinicalTrials.gov
Bladder ca Tumor of urinary bladder
Bladder cancer Urinary bladder malignant tumor
Bladder carcinoma Tumor of the urinary bladder
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Systematic Reviews and Meta-Analysis (PRISMA) [4].
First, we searched MEDLINE (Ovid MEDLINE® 1946
to Present with daily update; searched 31.08.2012), an
electronic database of biomedical literature, for any
reports on the four relevant urological tumors with high
incidences and mortality rates (prostatic, urinary bladder,
kidney, and testicular neoplasms) based on recent data
publically available from the International Agency for
Research on Cancer of the World Health Organization
[1]. We used medical subject heading (MeSH) terms
on prostatic (prostatic neoplasms/), kidney (kidney
neoplasms/), urinary bladder (urinary bladder neoplasms/)
and testicular neoplasms (testicular neoplasms/). The
search included all reports published from 2001 to 2011.
Then, we narrowed our search strategy by limiting it to
randomized controlled trials, clinical controlled trials,
meta-analyses, and case reports using a limit function
provided by MEDLINE (‘publication type’). For definitions
of the urological tumors provided by MEDLINE see
Table 1. The search strategy for reports on ‘urinary
bladder neoplasm/’ in MEDLINE is displayed as an
example in Table 2.
Second, we searched the publically available trial register
ClinicalTrials.gov for studies on the relevant urological
neoplasms (www.clinicaltrials.gov; searched: 13.09.12).
ClinicalTrials.gov is a registry for studies conducted in the
United States and worldwide. It currently contains data
sets on 132,156 trials originating from 179 countries
(www.clinicaltrials.gov). We used the search function
provided by ClinicalTrials.gov to identify studies on pros-
tatic, kidney, urinary bladder and testicular neoplasms. The
search function expands the search strategy according to an
internal algorithm. The search strategy for studies on kidney
cancer in ClinicalTrials.gov is displayed in Table 3 as an
example. We searched for studies with start dates between
2005 and 2011 because prospective trial registration has
been a requirement since July 1, 2005 only (www.icmje.org).
We evaluated the increase of newly published reports
per year using linear regression and presented all results
with 95% confidence intervals (CI). Statistical analysis
was performed with the IBM SPSS Statistics 19 soft-
ware package. All of the tests were two-sided, and aTable 1 Definitions of the urological tumors as used by
MEDLINE
Prostatic neoplasms Tumors or cancers of the prostate
Kidney neoplasms Tumors or cancers of the kidney
Urinary bladder
neoplasms
Tumors or cancers of the urinary bladder
Testicular neoplams Tumors or cancer of the testis, germ cell
tumors (germinoma) of the testis constitute
95% of all testicular neoplasmsp value <0.05 was considered statistically significant
(SPSS 19 software, IBM SPSS, Chicago, IL).
Results
Our search strategy identified 85,238 uro-oncological
citations in MEDLINE published between 2001 and
2011 (for details see Figure 1). Of these, 46,824 (54.9%)
reported on prostatic neoplasms, 19,152 (22.5%) reported
on kidney neoplasms, 13,736 (16.1%) reported on bladder
neoplasms, and 5,526 (6.5%) reported on testicular
neoplasms. The number of new publications per year
increased significantly over the evaluated time period
for prostatic, kidney and urinary bladder neoplasms
(all <0.0001). Citations on prostatic neoplasms increased
the most, with a median increase of 250.7 more publica-
tions than the year before (95% CI 214.2-287.2). There
were 2828 citations on prostatic neoplasms in 2001 and
5666 in 2011. Interestingly, new reports on kidney cancer
increased with a median increase of 106 more new
publications per year (95% CI 96.3-115.6) far more
than the increase in reports on urinary bladder cancer
(40.8 more new publications/year, 95% CI 33.5-48.1).
We identified no significant increase in the number ofBladder neoplasms Tumor of the bladder
Bladder tumors Tumor of bladder
Cancer of bladder Tumor bladder
Cancer of the bladder Neoplasm of urinary bladder
Cancer of the urinary bladder Neoplasm of the urinary bladder
Cancer of urinary bladder Neoplasm of the bladder
Carcinoma of bladder Neoplasm of bladder
Carcinoma of the bladder Malignant neoplasm of the bladder
Carcinoma of the urinary bladder Carcinoma of urinary bladder
85238 citations  through 
database searching 
Narrowing of 46824 
citations using a 
limitation function 
provided by MEDLINE 
(‚publication type‘)
46824 citations 
reporting on prostatic 
neoplasms
1404 citations indexed 
as RCTs 
129 citations indexed 
as CCTs
263 citations indexed 
as MAs 
2232 citations indexed 
as CRs
19152 citations 
reporting on kidney 
neoplasms
13736 citations 
reporting on urinary 
bladder neoplasms
5526 citations  
reporting on testicular 
neoplasms
Narrowing of 19152 
citations using a 
limitation function 
provided by MEDLINE 
(‚publication type‘)
193 citations indexed 
as RCTs 
30 citations indexed  
as CCTs
66 citations indexed  
as MAs 
6013 citations indexed 
as CRs
Narrowing of 13736 
citations using a 
limitation function 
provided by MEDLINE 
(‚publication type‘)
249 citations indexed 
as RCTs 
41 citations indexed  
as CCTs
128 citations indexed  
as MAs 
2304 citations indexed 
as CRs
Narrowing of 5526 
citations using a 
limitation function 
provided by MEDLINE 
(‚publication type‘)
39 citations indexed  
as RCTs 
6 citations indexed  
as CCTs
30 citations indexed  
as MAs 
1817 citations indexed 
as CRs
Figure 1 Search flow chart (Ovid MEDLINE®). RCTs, randomized controlled trials; CCTs, clinical controlled trials; MAs, meta-analyses; CRs, case reports.
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more new publications/year, 95% CI −3.2-15.2, p = 0.17;
Table 4).
The limitation focusing on published reports of studies
indexed in MEDLINE as randomized controlled trials re-
vealed 1,885 studies published between 2001 and 2011:
1404 (74.5%) on prostatic neoplasms, 193 (10.2%) on kidney
neoplasms, 249 (13.2%) on urinary bladder neoplasms, and
39 (2.1%) on testicular neoplasms. For details see Figure 1.
While the number of newly published citations per year on
randomized controlled trials increased significantly for re-
ports on prostatic (p = 0.001) and kidney cancer (p = 0.005),
we identified no significant differences among publications
on urinary bladder (p = 0.09) and testicular (p = 0.44)
neoplasms. With an approximate increase of 8 more new
citations per year, the majority of randomized controlled
trials were published on prostatic neoplasms (Table 4).
The number of publications of uro-oncological studies
indexed in MEDLINE as clinically controlled trials was
marginal and showed no statistical significant increase
of new publications per year for any tumor entity.
Remarkably, the number of publications on urinary blad-
der cancer showed a decreasing trend per year, but the
decrease was not statistically significant (p = 0.05). The
numbers of publications per year of reports indexed
as meta-analyses increased significantly for prostatic
(p < 0.0001), kidney (p = 0.001), and urinary bladder
neoplasms (p = 0.006). However, the discovered maximum
median increase of 3 more new meta-analyses per year for
prostatic neoplasms is quite small. Interestingly, the num-
bers of new case-reports on kidney neoplasms amountedto a median increase of approximately 23 more new cita-
tions per year, a significant increase (p < 0.0001), while all
other urological tumor entities remained on the same level
over the investigated time period (Table 4).
We identified a total of 3,114 registered studies on
prostatic, kidney, urinary bladder and testicular neo-
plasms with start dates between 2005 and 2011 from
our search in ClinicalTrials.gov (Table 2). For details
see Figure 2. Approximately 85% of these registered
studies involved prostatic (1413 studies, 45%) or kidney
neoplasms (1251 studies, 40%). Over a time period of
7 years (2005–2011), only 354 studies (11%) were reg-
istered on management of urinary bladder neoplasms.
With 96 registered studies (3%), the quantity of entries on
testicular cancers lagged far behind the other evalu-
ated tumors. Approximately 30% of the total number
of studies on prostatic (33.2%), kidney (30.8%) and urinary
bladder neoplasms (27.7%) were registered as randomized
controlled trials, while a much lower number (19.8%)
of randomized controlled trials concerned testicular
neoplasms (Table 5).
We also evaluated the status of uro-oncological
studies as registered in ClinicalTrials.gov. However,
we did not identify statistically significant differences
between the various status classifications for each tumor
entity (Table 5). We considered the statuses ‘recruiting’,
‘active, not recruiting’, ‘not yet recruiting’, ‘enrolling by
invitation’, and ‘completed’ as potentially positive for a
subsequent analysis of the trial results; approximately
90% of the studies met these requirements (prostatic
neoplasms: 90%; kidney neoplasms: 90%; urinary bladder
Table 4 Uro-oncological publications in Ovid MEDLINE (2001–2011)
Total Increase of new publications per year p value
(95% Confidence interval)
Total publications
Prostatic neoplasms 46824 250.7 (214.2-287.2) <0.0001
Kidney neoplasms 19152 106 (96.3-115.6) <0.0001
Urinary bladder neoplasms 13736 40.8 (33.5-48.1) <0.0001
Testicular neoplasms 5526 6 (−3.2-15.2) 0.17
Publications indexed as randomized controlled trials
Prostatic neoplasms 1404 8.1 (4.2-12) 0.001
Kidney neoplasms 193 1.9 (0.7-3) 0.005
Urinary bladder neoplasms 249 0.5 (−0.2-2.4) 0.09
Testicular neoplasms 39 0.1 (−0.2-0.5) 0.44
Publications indexed as clinical controlled trials
Prostatic neoplasms 129 0.2 (−1.6-1.2) 0.76
Kidney neoplasms 30 −0.3 (−0.6-0.1) 0.12
Urinary bladder neoplasms 41 −0.4 (−0.8-0) 0.05
Testicular neoplasms 6 −0.1 (−0.2-0) 0.15
Publications indexed as meta-analysis
Prostatic neoplasms 263 3 (2–3.9) <0.0001
Kidney neoplasms 66 1.3 (0.7-1.9) 0.001
Urinary bladder neoplasms 128 1.6 (0.6-2.6) 0.006
Testicular neoplasms 30 0.4 (−0.1-0.8) 0.06
Publications indexed as case reports
Prostatic neoplasms 2232 0.5 (−3.5-4.4) 0.8
Kidney neoplasms 6013 22.6 (15.6-29.5) <0.0001
Urinary bladder neoplasms 2304 0 (−3.4-3.5) 0.98
Testicular neoplasms 1817 0 (−4.3-4.4) 0.99
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minority of studies had ‘suspended’, ‘terminated’, or
‘withdrawn’ statuses (prostatic neoplasms: 9.4%; kidney
neoplasms: 10%; urinary bladder neoplasms: 9%; testicular
neoplasms: 8%).469 RCTs 
416 Non-RCTs 
1413 studies with start 
dates between 2005 
and 2011 
885 studies with other 
start dates excluded
2298 registered studies 
involving prostatic 
neoplasms
1413 studies screened
385 RCTs 
866 Non-RCTs 
1251 studies with start 
dates between 2005 
and 2011 
729 studies with other 
start dates excluded
1980 registered studies 
involving kidney 
neoplasms
1251 studies screened
Figure 2 Search flow chart (ClinicalTrials.gov). RCTs, randomized controDiscussion
We analyzed the publication trends of the four relevant
urological neoplasms and found that a tremendous
increase of published uro-oncological literature has
occurred over the past 10 years. However, the numbers of98   RCTs 
256 Non-RCTs 
354 studies with start 
dates between 2005 
and 2011 
236 studies with other 
start dates excluded
590 registered studies 
involving urinary 
bladder neoplasms
354 studies screened
19 RCTs 
77 Non-RCTs 
96 studies with start 
dates between 2005 
and 2011 
128 studies with other 
start dates excluded
224 registered studies 
involving testicular 
neoplasms
96 studies screened
lled trials; Non-RCTs, non-randomized controlled trials.
Table 5 Uro-oncological studies registered in ClinicalTrials.gov
Total Randomized
studies
Recruiting Active, not
recruiting
Not yet
recruiting
Enrolling by invitation Completed Suspended Terminated Withdrawn Others*
Prostatic neoplasms 1413 469 536 300 23 20 399 11 99 23 2
(33.2%) (37.9%) (21.2%) (1.6%) (1.4%) (28.2%) (0.8%) (7%) (1.6%) (0.1%)
Kidney neoplasms 1251 385 518 247 26 15 317 12 86 27 3
(30.8%) (41.4%) (19.7%) (2.1%) (1.2%) (25.3%) (1.0%) (6.9%) (2.2%) (0.2%)
Urinary bladder neoplasms 354 98 159 63 5 6 89 0 23 9 0
(27.7%) (44.9%) (17.8%) (1.4%) (1.7%) (25.1%) (0%) (6.5%) (2.5%) (0%)
Testicular neoplasms 96 19 46 22 1 0 19 1 4 3 0
(19.8%) (47.9%) (22.9%) (1%) (0%) (19.8%) (1%) (4.2%) (3.1%) (0%)
* Available, approved for marketing, no longer available.
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http://www.biomedcentral.com/1471-2490/13/56reports on urinary bladder neoplasms lag behind compared
to kidney and prostate cancer research. Additionally,
the vast majority of uro-oncological trials registered
in ClinicTrials.gov were on prostatic and kidney neoplasms;
only a small number addressed urinary bladder cancer.
We found that the total number of publications per
year increased significantly for the combined urological
tumor entities over the investigated time period. This
development reflects the overall increase in the number
of biomedical publications electronically available in
databases such as MEDLINE. A total of 724,831 new
citations were added to MEDLINE during 2011 [5].
With this rapidly increasing amount of knowledge, it
is almost impossible for physicians to quickly filter
out irrelevant evidence and to keep up-to-date with
contemporary knowledge [6,7]. This difficulty is even
exacerbated by the explosion of the types of publications
currently available.
However, in contrast to these evaluations, we determined
that the quantity of reports of randomized controlled trials
for prostate and kidney cancer, which are indispensable for
the evaluation of interventions, has increased significantly;
however, for bladder and testicular neoplasms, this promis-
ing pattern was not clearly evident. This fact indicates that
the prevalence of a tumor might not be reflected in the
number of published reports of studies with a design
not so prone to bias. Regarding the total number of
publications in MEDLINE and registered studies in
ClinicalTrials.gov, the level of research activity seems
to be lower in bladder cancer compared to prostate
cancer and renal cell carcinomas. Additionally, the
publication of new uro-oncological studies indexed in
MEDLINE as controlled clinical trials either was marginal
or even declined in recent years. This development is in
direct contrast to the clinical relevance of this tumor entity;
it seems that the research activity on urothelial carcinoma
has been overshadowed by scientific developments in
kidney and prostate cancer research.
A recent evaluation by Bachir et al. also supports this
conclusion [8]. The authors searched MEDLINE for
randomized controlled trials published between 1995
and 2010. They concluded that only 238 randomized
controlled trials had been published for bladder cancer
over this time period. Furthermore, the quality of trials
assessed was low. Only half of them had a sample
size >100 patients, and only a small percentage of stu-
dies were double-blinded (8.0%). Additionally, less than
one-third of the studies reported an appropriate power
calculation [8]. The authors concluded that randomized
controlled trials are therefore under-utilized in bladder
cancer research [8]. This corresponds to our results,
which highlight that urothelial bladder cancer is under-
represented in the literature compared to other urological
tumor entities.The number of uro-oncological citations indexed in
MEDLINE as clinically controlled trials was marginal,
and the number of meta-analyses on prostatic neoplasms
per year is still very low. In certain clinical contexts,
i.e., surgical therapy, it is not always feasible to take into
account factors that might lower the potential risk of
bias, such as blinding of participants and personnel.
Thus, increasing the literature on prostatic neoplasms
has become a crucial issue. Therefore, we agree with
Bachir et al. in their demand for more randomized con-
trolled trials with larger sample sizes to optimize the diag-
nostic and treatment strategies for patients with bladder
cancer [8]. However, we believe this should not be limited
to randomized controlled trials only. Also controlled cli-
nical trials, systematic reviews and meta-analyses can con-
tribute to the evidence-base that allows physicians
optimally treat their patients.
We found no significant increase in the number of
uro-oncological case reports on prostatic, urinary
bladder or testicular cancer. The rising number of case re-
ports on kidney cancer compared to other uro-oncologic
tumors might be linked to the development of targeted
therapies. The clinical implementation of these new drugs
has provided completely new treatment options and
allowed physicians to gain experience in detecting new
adverse events. However, these results are usually published
as case reports.
We also searched the publically available trial register
ClinicalTrials.gov for uro-oncological studies with start
dates between 2005 and 2011. Clinical Trials.gov is one
of the most popular trial registers worldwide and contains
more than 90,000 studies (www.clinicaltrials.gov). We found
that approximately 85% of the identified uro-oncological
studies were registered as involving prostatic or kidney
neoplasms. As for urothelial neoplasms, the number
of conducted and ongoing trials is far lower, which
supports our observation that urothelial bladder neoplasms
are neglected in the literature. The fact that 30% of the
(few) identified studies on prostate, kidney and urothelial
bladder neoplasms were randomized trials, however, is a
potentially positive sign of the quality of uro-oncologic
research; additionally, the frequency of randomized trials
was just as high for urothelial bladder cancer. Only the
number of randomized trials on testicular cancer showed a
significantly lower number of reported trials (19.8%),
which might reflect the low incidence of this tumor
and its excellent clinical outcome due to current thera-
peutic approaches. Another positive finding is that 90% of
the uro-oncological studies in ClinicalTrials.gov were listed
with a potentially positive registration status that will
allow for subsequent analyses of the trial results.
We can only assume that the total numbers of publica-
tions identified in MEDLINE and ClinicalTrial.gov are
representative of overall research activity in uro-oncology
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process, and many studies are not published due to a num-
ber of reasons [6,9,10]. There are certainly additional stu-
dies that have not been published in MEDLINE–indexed
journals. Searching additional databases, such as Embase
or the Cochrane Central Register of Controlled Trials,
might be necessary to identify additional related studies.
However, some studies might only be identifiable by
hand-searching journals that do not publish in English
[11-13]. Additionally, we want to point out that the crude
number of trials is certainly not associated with the overall
quality of the reported trials published in MEDLINE. A
possible limitation of our evaluation of the registered stu-
dies in ClinicalTrials.gov is the fact that the investigators
must register their trials and must update the trial registra-
tions regularly. Thus, we cannot guarantee that our results
are actually relevant. However, the International Committee
of Medical Journal Editors began promoting trial registra-
tion in 2005 and defined July 1, 2005 as the key date for
prospective trial registration (www.icmje.org). A recent
evaluation found that the vast majority of published trials
in the field of urology (83%) have been registered since
2006 [14]. Therefore, we are confident that our evaluation
considers a representative overview of the international
landscape of uro-oncological study.
Whether scientific research on urinary bladder cancer
is not as currently interesting as research on renal or
prostate cancer remains to be determined. From an eco-
nomic point of view, research on bladder neoplasms
should be extremely important because the therapy and
follow-up in this patient cohort are extremely expensive
[3]. Approximately 75–85% of patients with bladder cancer
present with superficially disease that does not invade the
muscles [15] and is treated by local therapy, such as trans-
urethral resections. Transurethral resection is regarded as
the gold standard of treatment [15], and its use has chan-
ged very little over the last decades. After decades of
research, no biomarkers for recurrence and progression
are commercially available with the required sensitivity and
specificity [16,17]. Moreover, the typical method for the
prevention of recurrence of non-muscle invasive bladder
cancer has not changed. Only approximately 20% of
bladder cancer patients present with muscle invasive
neoplasms that require additional neo-adjuvant or adjuvant
chemotherapy [18]. The only true innovation in this field is
a second-line cisplatin-containing combination chemothe-
rapy [19]. There have also been no fundamental changes in
the performance of artificial urinary diversion in the last
decade. Regarding the development of new surgical tech-
niques for advanced bladder cancer, this tumor is clearly
overshadowed by the implementation of new surgical treat-
ments for kidney and prostate cancer (i.e., open versus
laparoscopic versus robotic approaches) [20,21]. Overall,
the pharmaceutical and equipment manufacture marketsrevolve around prostate and kidney neoplasms almost ex-
clusively (i.e., for medical tumor therapy, androgen suppres-
sion therapy, and surgical techniques).
A provoking question arises: Does industry determine
uro-oncological research activity, or do uro-oncologists
simply have no new, improved scientific approaches to
implement? We believe that even when the quality or
outcome of diagnostics and therapeutic procedures is
good, further improvements and research are still
warranted.
Conclusions
The total number of publications in urologic oncology
has been rising continuously over recent years, particularly
in the form of randomized trials on prostate and kidney
cancers. Strikingly, although bladder cancer is one of the
most common malignancies in both men and women,
relatively few studies have been conducted on urothelial
carcinomas of the bladder. Clinical research on neoplasms
of the urothelial bladder must be explicitly addressed and
supported.
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